Chemical Namebelatacept
Dosage FormInjection (intravenous; 250 mg)
Drug ClassSelective T-cell costimulation blockers
CompanyBristol Myers Squibb
Approval Year2011


  • Indicated in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids for prophylaxis of organ rejection in adult patients receiving a kidney transplant.
Document TitleYearSource
Nulojix (belatacept) Prescribing Information.2021Bristol-Myers Squibb Company, Princeton, NJ
Drug updated on 5/31/2023

More on this drug: Clinical Trials